Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection

Trial Profile

Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms INFIRE; INFIRE-001
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Aug 2012 Actual initiation date 17 Dec 2010 added as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top